To investigate whether CDK4/6 inhibition alone or in combination with BRAF and MEK inhibition alters metabolic pathways in melanoma, we utilised the BRAF mutant melanoma cell lines WM266.4 and A375 and specific inhibitors of CDK4/6 (palbociclib), BRAF (vemurafenib), and MEK (cobimetinib). The gene discussed is CDK4; the disease is melanoma.